X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9745) 9745
Magazine Article (12) 12
Book Chapter (7) 7
Book / eBook (5) 5
Dissertation (3) 3
Web Resource (3) 3
Book Review (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7728) 7728
pyrroles - therapeutic use (5902) 5902
male (4879) 4879
female (4210) 4210
middle aged (3212) 3212
animals (3021) 3021
atorvastatin calcium (2748) 2748
heptanoic acids - therapeutic use (2669) 2669
pyrroles - pharmacology (2457) 2457
aged (2375) 2375
adult (2039) 2039
indoles - therapeutic use (2039) 2039
oncology (1809) 1809
treatment outcome (1778) 1778
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1548) 1548
atorvastatin (1523) 1523
pyrroles - administration & dosage (1500) 1500
pharmacology & pharmacy (1491) 1491
antineoplastic agents - therapeutic use (1487) 1487
mice (1351) 1351
sunitinib (1285) 1285
pyrroles - adverse effects (1269) 1269
cancer (1231) 1231
anticholesteremic agents - therapeutic use (1063) 1063
carcinoma, renal cell - drug therapy (1057) 1057
statins (1041) 1041
kidney neoplasms - drug therapy (1014) 1014
pyrimidines - therapeutic use (960) 960
rats (953) 953
care and treatment (843) 843
analysis (814) 814
expression (802) 802
cardiac & cardiovascular systems (780) 780
heptanoic acids - pharmacology (772) 772
cholesterol (745) 745
dose-response relationship, drug (745) 745
therapy (706) 706
research (695) 695
cholesterol, ldl - blood (674) 674
cell line, tumor (668) 668
protein kinase inhibitors - therapeutic use (655) 655
aged, 80 and over (648) 648
indoles - adverse effects (640) 640
risk factors (634) 634
heptanoic acids - administration & dosage (632) 632
drug therapy (628) 628
kidney neoplasms - pathology (627) 627
simvastatin (627) 627
double-blind method (618) 618
inflammation (588) 588
angiogenesis inhibitors - therapeutic use (584) 584
time factors (581) 581
indoles - pharmacology (578) 578
indoles - administration & dosage (564) 564
niacinamide - analogs & derivatives (551) 551
efficacy (540) 540
medicine & public health (534) 534
disease models, animal (525) 525
hypercholesterolemia - drug therapy (525) 525
metastasis (522) 522
drug therapy, combination (518) 518
pyrroles - chemistry (513) 513
tyrosine kinase inhibitor (494) 494
immunology (486) 486
tumors (485) 485
retrospective studies (478) 478
simvastatin - therapeutic use (477) 477
angiogenesis (476) 476
apoptosis (467) 467
endothelial growth-factor (465) 465
clinical trials as topic (458) 458
medicine, general & internal (456) 456
health aspects (455) 455
prospective studies (455) 455
antineoplastic agents - pharmacology (453) 453
indoleamine-pyrrole 2,3,-dioxygenase - metabolism (452) 452
abridged index medicus (445) 445
survival (444) 444
interferon-alpha (438) 438
prognosis (438) 438
atherosclerosis (437) 437
disease (436) 436
sulfonamides - therapeutic use (435) 435
biochemistry & molecular biology (431) 431
antineoplastic agents (427) 427
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (420) 420
urology & nephrology (418) 418
pyrimidines - pharmacology (415) 415
pravastatin (412) 412
safety (411) 411
research article (410) 410
pyrroles - pharmacokinetics (408) 408
carcinoma, renal cell - pathology (404) 404
antineoplastic agents - adverse effects (402) 402
inhibition (402) 402
peripheral vascular disease (402) 402
disease-free survival (401) 401
prevention (400) 400
heptanoic acids - adverse effects (399) 399
antimitotic agents (398) 398
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9327) 9327
Japanese (146) 146
German (143) 143
French (109) 109
Chinese (72) 72
Spanish (55) 55
Russian (50) 50
Italian (42) 42
Polish (16) 16
Hungarian (13) 13
Dutch (12) 12
Portuguese (10) 10
Ukrainian (6) 6
Czech (5) 5
Turkish (4) 4
Danish (2) 2
Korean (2) 2
Norwegian (2) 2
Swedish (2) 2
Lithuanian (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European urology, ISSN 0302-2838, 2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | UROLOGY & NEPHROLOGY | PHASE-II | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 2016, Volume 50, pp. 109 - 117
... are approved for first-line or later-line use in the treatment of patients with mRCC [1–3] . Among these agents, 1 is a monoclonal antibody targeting vascular endothelial... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | PROGRESSION-FREE SURVIVAL | 1ST-LINE SUNITINIB | BLIND PHASE-III | OPEN-LABEL | INTERFERON-ALPHA | ONCOLOGY | 2ND-LINE TREATMENT | EXPRESSION LEVELS | CANCER-SPECIFIC SURVIVAL | CLINICAL-PRACTICE | DOSE TITRATION | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2019, Volume 80, Issue 4, pp. 1029 - 1072
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 05/2017, Volume 2017, Issue 5, p. CD012657
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5, pp. 482 - 487
Journal Article
Journal Article
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 11/2016, Volume 2016, Issue 11, p. CD012437
Background We performed a systematic review, a standard meta‐analysis and network meta‐analysis (NMA), which updates the 2009 Cochrane Overview, 'Biologics for... 
Certolizumab Pegol | Pyrroles | Rheumatology | Antirheumatic Agents | Rituximab | Antibodies, Monoclonal | Arthritis, Rheumatoid | Disease Progression | Antibodies, Monoclonal, Humanized | Pyrimidines | Etanercept | Piperidines | Treatment Failure | Rheumatoid arthritis | Biologics | Biological Products | Interleukin 1 Receptor Antagonist Protein | Treatment [Pharmacological interventions] | Methotrexate | Network Meta‐Analysis | Medicine General & Introductory Medical Sciences | RANDOMIZED-CONTROLLED-TRIAL | ALPHA MONOCLONAL-ANTIBODY | MEDICINE, GENERAL & INTERNAL | TREAT-TO-TARGET | INTERLEUKIN-1 RECEPTOR ANTAGONIST | RECEIVING CONCOMITANT METHOTREXATE | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | ADALIMUMAB PLUS METHOTREXATE | ANTITUMOR NECROSIS FACTOR | PATIENT-REPORTED OUTCOMES | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Antibodies, Monoclonal - therapeutic use | Methotrexate - therapeutic use | Rituximab - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Arthritis, Rheumatoid - drug therapy | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Certolizumab Pegol - therapeutic use | Network Meta-Analysis | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Etanercept - therapeutic use
Journal Article